Recombinant Human Type II inositol 3,4-bisphosphate 4-phosphatase (INPP4B), partial

1. Luciferase reporter assay revealed that miR-1290 directly bound to the 3'-UTR of INPP4B; the mutated seed sites in miR-1290 abrogated this effect. Double knockdown of INPP4B and miR-1290 promoted CRC cell proliferation, suggesting miR-1290 promoted CRC cell proliferation by targeting INPP4B. PMID: 28915933
2. High INPP4B expression is associated with melanoma. PMID: 28656250
3. INPP4B role in regulating phosphatidylinositol-3-kinase signaling in the triple-negative breast cancer cells. PMID: 28196852
4. Fisher's exact SubID was used to reveal EVI1 as a transcriptional regulator of INPP4B in AML; a finding which was validated in vitro. Next, we used CoxPH SubID to conduct a pan-cancer analysis of INPP4B's prognostic significance PMID: 29415082
5. INPP4B acted as a tumour suppressor in human prostate cancer PMID: 28261855
6. INPP4B is down-regulated in colorectal adenocarcinomas. PMID: 28982866
7. Collectively, these results suggest that INPP4B may function as an oncogenic driver in colon cancer, with potential implications for targeting INPP4B as a novel approach to treat this disease. PMID: 26411369
8. Study shows that IRF2 knockdown inhibits growth, colony formation of OCI/AML-2, OCI/AML-3, and THP-1 cells. In addition, IRF2 knockdown induces apoptosis of acute myeloid leukemia (AML) cells by regulating apoptotic effectors. Further mechanism analysis shows that INPP4B contributes to the effects of IRF2 on apoptosis and growth of AML cells. Thus, IRF2 serves as an important regulator in AML by targeting INPP4B. PMID: 28579269
9. Immunohistochemical assessment of nestin and INPP4b provides an accurate, accessible and inexpensive tool to identify basal-like breast cancer subtype in the clinically problematic setting of weak oestrogen receptor positivity PMID: 27402148
10. This study sthe identification of a novel small transcript variant of INPP4B (INPP4B-S) that has a role in promoting proliferation of colon and breast cancer cells. INPP4B-S differed from full length INPP4B (INPP4B-FL) by the insertion of a small exon between exons 15 and 16 and the deletion of exons 20-24. PMID: 28189677
11. presented data indicate that INPP4B is crucial for docetaxel-resistant PCa cell survival, potentially by regulating EMT through the PI3K/Akt signaling pathway PMID: 27318090
12. Low PINPP4B expression is associated with luminal breast cancer. PMID: 28224609
13. Mechanism analyses found polyphosphate 4-phosphatase type II (INPP4B) was the target of miR-937, miR-937 directly bound to the 3'UTR of INPP4B, knockdown of INPP4B in A549 with miR-937 inhibitor promoted anchorage -dependent and -independent growth, suggesting miR-937 contributed to cell proliferation of lung cancer PMID: 27179609
14. INPP4B expression is associated with enhanced ATM-dependent DNA double strand break repair, which could be mediated by p65 nuclear translocation. PMID: 27342972
15. Studies indicate that phosphatidylinositol 4-phosphate phosphatase (INPP4B) that acting as tumor suppressors by antagonizing AKT signaling at endosomes. PMID: 26700619
16. The incidence of INPP4B loss of heterozygosity was significantly higher in the triple-negative breast tumor subtype and positively correlated with PTEN loss of heterozygosity. PMID: 26577950
17. Data show that activation of serum- and glucocorticoid-regulated kinase 3 (SGK3) plays an important role in inositol polyphosphate 4-phosphatase type II (INPP4B)-mediated melanoma cell proliferation. PMID: 26573229
18. Study provides evidence that INPP4B loss can promote follicular-like thyroid cancer progression and metastasis in the context of PTEN haploinsufficiency through the isoform-specific regulation of AKT signaling at the endosomes. PMID: 25883022
19. Studies in human tissues suggest that reductions in INPP4B and PTEN co-occur in human thyroid and endometrial cancers. INPP4B may therefore be an important regulator of cancer progression, especially in the context of PTEN insufficiency. PMID: 25883023
20. Given that INPP4B loss has been found in 40% of ovarian cancer patients, this study provides the rationale for establishing INPP4B as a biomarker of PARP inhibitor response. PMID: 25868852
21. Epigenetic inactivation of INPP4B is one of the key mechanisms in activating PI3K/AKT signaling cascade and playing a role in the tumorigenesis of nasopharyngeal carcinoma. PMID: 25126743
22. There were no significant associations of PIK3CA copy number, pAKt, or INPP4B with trastuzumab efficacy. PMID: 25542038
23. INPP4B is a novel suppressor of oncogenic PKC signaling, further emphasizing the role of INPP4B in maintaining normal physiology of the prostate epithelium and suppressing metastatic potential of prostate tumors. PMID: 25248616
24. INPP4B overexpression is associated with therapy resistance in acute myeloid leukemia PMID: 25736236
25. ). We find that RAD50 and INPP4B expression levels have a synergistic influence on breast cancer survival, possibly through their effects on treatment response. PMID: 25528023
26. Seventy-nine percent of the ovarian cancers demonstrated loss of INPP4B, most frequently in serous and endometrioid cancer subtypes. PMID: 26189250
27. ERalpha plays a protective role in bladder cancer initiation and growth at least partly via modulating the INPP4B/Akt pathway. PMID: 25277204
28. A previously unsuspected and clinically relevant role for INPP4B gain of function as a mediator of chemoresistance and poor survival outcome in AML independent of its phosphoinositide phosphatase function. PMID: 25736313
29. An association of an INPP4B polymorphism (rs13102150) with multiple sclerosis was observed PMID: 25129256
30. the combination of INPP4B gene transfection and PARP inhibitor had a synergistic antitumor effect on PC3 cells PMID: 24837011
31. Breast cancers harboring oncogenic PIK3CA activate SGK3 signaling while suppressing Akt, indicative of oncogenic functions for both INPP4B and SGK3 in these tumors. PMID: 25458846
32. INPP4B is highly expressed in intermediate cells within proliferative inflammatory atrophic ducts, and expression is reduced in prostate carcinoma PMID: 25284366
33. INPP4B regulates PI3K/Akt signaling and exerts a tumor suppressor effect, impacting the proliferative, invasive, and tumorigenic capacity of melanoma cells. PMID: 24288008
34. INPP4B, which dephosphorylates PI(3,4)P2 to PI(3)P, is essential for macropinocytosis. PMID: 24591580
35. INPP4B has protein phosphatase activity. different residues within the catalytic site of INPP4B are responsible for activity with lipid and protein substrates and for substrate specificity than for PTEN. PMID: 24070612
36. Codepletion of INPP4B and hexokinase 2 markedly sensitized radioresistant laryngeal cancer cells to irradiation or anticancer drug. PMID: 24051093
37. INPP4B depletion significantly attenuated radiation-induced increases in Akt phosphorylation. PMID: 22895072
38. Inositol phosphatase and bone mass: role of INPP4b. PMID: 22377302
39. INPP4B: the new kid on the PI3K block. PMID: 21487159
40. INPP4B functions as a tumor suppressor by negatively regulating normal and malignant mammary epithelial cell proliferation through regulation of the PI3K/Akt signaling pathway PMID: 21127264
41. INPP4B has been identified as a tumor suppressor. Loss of heterozygosity (LOH) is found at the INPP4B locus in basal-like breast cancers, as well as in a significant fraction of ovarian cancers. PMID: 19647222

Show More

Hide All

HGNC: 6075

OMIM: 607494

KEGG: hsa:8821

STRING: 9606.ENSP00000262992

UniGene: Hs.176376